| Biomarker ID | 455 |
| PMID | 19773444 |
| Year | 2009 |
| Biomarker | CYR61 (Angiogenic inducer 61); MASPIN (Serpin peptidase inhibitor); AGR2 (Anterior gradient 2 homologue); |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Downgregulated in Docetaxel- resistant PC3-Rx cells [(CYR61 Angiogenic inducer 61 (1.5 fold); MASPIN Serpin peptidase inhibitor (1.5 fold); AGR2 Anterior gradient 2 homologue (2.4 fold)]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(SERPINB5):- TAp63 pathway,ATF2 transcription factor network,p53 activity regulation, p53 signaling pathway |
| Experiment | Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells |
| Type of Biomarker | Potential Predictive |
| Cohort | Docetaxel-sensitive PC3 cells and Docetaxel resistant PC3-Rx cells developed by Docetaxel dose escalation were selected for this analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | iTRAQ-mass spectrometry |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Human patient cohort |
| Technical Name | CCN1, SERPINB5, AGR2 |